The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People’s Republic of China

INTRODUCTION: Clinical evidence comparing chemotherapy and tyrosine kinase inhibitors (TKIs) as second-line therapy for epidermal growth factor receptor (EGFR) wild-type non-small-cell lung cancer (NSCLC) are conflicting. METHODS: We retrospectively reviewed stage IV EGFR wild-type NSCLC patients wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianlin, Ding, Guozheng, Zhang, Xueyan, Jin, Bo, Lou, Yuqing, Zhang, Yanwei, Wang, Huiming, Wu, Dan, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079695/
https://www.ncbi.nlm.nih.gov/pubmed/27799795
http://dx.doi.org/10.2147/OTT.S119341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079695/
https://www.ncbi.nlm.nih.gov/pubmed/27799795
http://dx.doi.org/10.2147/OTT.S119341

Ejemplares similares